An interventional study of PRP infiltration in Knee Osteoarthritis, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli — 13 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Knee · Istituto Ortopedico Rizzoli.
Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 28th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →13 of the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–60
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–65
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 65–80
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–85
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–75
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2023.
This study's planned enrollment of 30 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 50 across the 25 interventional studies, 105 across the 6 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
4 of the studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06726629Istituto Ortopedico RizzoliCrosscultural Adaptation And Validation Of The Italian Version Of The New Knee Society Knee Scoring System | 2026-11 |
| NCT06251752Istituto Ortopedico RizzoliLong Term Evaluation of Clinical and Radiologic Results on Femoro-patellar Joint After High Tibial Osteotomy | 2026-12 |
| NCT06040957Istituto Ortopedico RizzoliBone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis | 2027-01 |
| NCT06490770Istituto Ortopedico RizzoliAnalysis of the Pathophysiological and Functional State of the Knee Joint | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study consists of 3 phases (enrollment, infiltrative procedure, and controls):
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: PRP infiltration
a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician. It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site. PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat. PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations.
International Knee Documentation Committee score
This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines 3 categories: symptoms, sports activity, and knee function.
Time frame: 6 months
International Knee Documentation Committee score
This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathology. The questionnaire examines 3 categories: symptoms, sports activity, and knee function.
Time frame: baseline, 1, 3, 6, 12 months
Tegner Activity Level Scale
It is a questionnaire to find out the patient's level of physical activity
Time frame: baseline, 1, 3, 6, 12 months
Knee Injury and Osteoarthritis Outcome Score
The full questionnaire consists of five subscales and they cover: pain (9 items), symptoms (7 items of which two relate to stiffness), functions and activities of daily living (17 items) physical function, sports activities and leisure (5 items) and quality of life in relation to the knee (4 items). All items in the relevant subscales have the same response mode, use a 5-point Likert scale, and each question is assigned a score from 0 to 4, where 0 indicates "no difficulty" and 4 "a severe difficulty). Score range 0-100 for each subscale.
Time frame: baseline, 1, 3, 6, 12 months
Visual Analogue Scale
visual analog scale consisting of a straight line segment (10 cm length), the ends of which correspond to "no pain" and "the strongest pain imaginable"
Time frame: baseline, 1, 3, 6, 12 months
objective parameter
range of motion and bilateral trans patellar and supra patellar circumferences for comparative analysis.
Time frame: baseline, 1, 3, 6, 12 months
Patient Acceptable Symptom State
Valuable tool for assessing patient satisfaction considering the patient's current degree of pain, function, and daily activity.
Time frame: baseline, 1, 3, 6, 12 months
Expectations of treatment efficacy
The patient should indicate at baseline what benefits he or she expects from the treatment.
Time frame: baseline
Overall judgment on treatment
The patient should indicate the degree of satisfaction related to the treatment performed at each follow-up.
Time frame: baseline, 1, 3, 6, 12 months
Tolerability assessment parameters:
All adverse events will be reported by filling out "Adverse event report forms" that will be kept with each patient's CRF (Case Report Form). The latter will document all medications taken additionally by the patient for pain control, indicating brand name, generic name, start and end of intake, and daily dose. Serious adverse events will be reported as per company procedure and the Ethics Committee will be informed, which will rule on whether patient enrollment should be discontinued.
Time frame: baseline, 1, 3, 6, 12 months
Platelet-rich plasma-Homologous (PRP-O) evaluation parameters
The quality of the administered Platelet-rich plasma- Homologous (PRP-O) will be assested by using standard blood parameters data as hematological control.
Time frame: baseline, 1, 3, 6, 12 months
Plan to share: Undecided
Started Oct 2023 (actual). Primary completion is estimated for Sep 2026, 35 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 35 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.